EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Fully Human Monoclonal Antibody Cocktail Provides Therapeutic Protection Against Botulinum Neurotoxin A1

Aki Yamaguchi, Takuhiro Matsumura, Masachika Azuma, Kazuhiro Suzuki, Masahiro Yutani, Sachiyo Akagi, Sho Amatsu, Nobuhide Kobayashi, Motohide Takahashi, Yukako Fujinaga

Toxins · 10.11.2026 · 18 (11) · 488

DOI: 10.3390/toxins18110488 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Toxins, online erschienen am 10.11.2026. Verfasst von Aki Yamaguchi und 9 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science (JSPS) KAK-ENHI, Japan Agency for Medical Research and Development.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Botulism is a fatal disease characterized by flaccid paralysis caused by botulinum neurotoxin (BoNT). In adults, human botulism is currently treated with equine-derived antitoxins, which have provided substantial clinical benefit and remain the mainstay of treatment. However, these equine antitoxin products carry a risk of adverse reactions due to heterologous proteins and have limitations in stable supply. Here, we developed three fully human monoclonal antibodies (HuMAbs)—BT-015, BT-175, and NT-320—against botulinum neurotoxin subtype A1 (BoNT/A1), a major cause of human botulism. BT-015 and BT-175 bound to recombinant LHN, which comprises the catalytic domain (light chain) and the N-terminal translocation domain of the heavy chain, whereas NT-320 bound to the C-terminal receptor-binding domain of the heavy chain (HC). Competition assays further showed that BT-015 and BT-175 recognize largely distinct binding sites within LHN. Each antibody showed neutralizing activity in mice, whereas the three-antibody cocktail provided the greatest protective effect and completely protected mice against the BoNT/A1 medium progenitor toxin complex (M-PTC) under the conditions tested. Moreover, treatment with the cocktail shortly after the onset of clinical signs following oral challenge with the BoNT/A1 large progenitor toxin complex (L-PTC) improved survival and promoted recovery from clinical signs. These findings highlight the therapeutic potential of the HuMAb cocktail for botulism.

Förderung

  • Japan Society for the Promotion of Science (JSPS) KAK-ENHI
  • Japan Agency for Medical Research and Development

Zitieren

APA

Yamaguchi, A., Matsumura, T., Azuma, M., Suzuki, K., Yutani, M., Akagi, S., Amatsu, S., Kobayashi, N., Takahashi, M., & Fujinaga, Y. (2026). A Fully Human Monoclonal Antibody Cocktail Provides Therapeutic Protection Against Botulinum Neurotoxin A1. Toxins, 18(11), 488. https://doi.org/10.3390/toxins18110488

Vancouver

Yamaguchi A, Matsumura T, Azuma M, Suzuki K, Yutani M, Akagi S, et al. A Fully Human Monoclonal Antibody Cocktail Provides Therapeutic Protection Against Botulinum Neurotoxin A1. Toxins. 2026;18(11):488. doi:10.3390/toxins18110488

BibTeX
@article{Yamaguchi2026,
  author = {Yamaguchi, Aki and Matsumura, Takuhiro and Azuma, Masachika and Suzuki, Kazuhiro and Yutani, Masahiro and Akagi, Sachiyo and Amatsu, Sho and Kobayashi, Nobuhide and Takahashi, Motohide and Fujinaga, Yukako},
  title = {A Fully Human Monoclonal Antibody Cocktail Provides Therapeutic Protection Against Botulinum Neurotoxin A1},
  journal = {Toxins},
  year = {2026},
  volume = {18},
  number = {11},
  pages = {488},
  doi = {10.3390/toxins18110488}
}
Kostenlos starten →